Comparative Effectiveness of Lipid-Modifying Agents [Internet]

Mukul Sharma; Mohammed Ansari; Karla Soares‐Weiser; Ahmed M Abou-Setta; Teik Chye Ooi; Margaret Sears; Fatemeh Yazdi; Alexander Tsertsvadze; David Moher

Abstract

1 min read

This evidence report was commissioned by the Agency for Healthcare Research and Quality (AHRQ) to address the following key questions: Key Question 1. For patients who require intensive lipid-modifying therapy, what are the comparative long-term benefits and rates of serious adverse events of coadministration of different lipid-modifying agents (i.e., a statin plus another lipid-modifying agent) compared with higher dose statin monotherapy? Key Question 2. Do these regimens differ in reaching LDL targets (or other surrogate markers), short-term side effects, tolerability, and/or adherence? Key Question 3. Compared with higher dose statins and to one another, do combination regimens differ in benefits and harms within subgroups of patients?

Related publications

Article2021

PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy

Kari A. Mäkelä, Jari Jokelainen, Ville Stenbäck, Juha Auvinen, Paul M Ridker, Mikko P. Tulppo, Juhani Leppäluoto, Sirkka Keinänen‐Kiukaanniemi, Karl‐Heinz Herzig

Article2020

Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives

Marco Alings, Olivier Descamps, B. Guillon, Margrét Leósdóttir, Aldo Maggioni, Lluís Recasens, Walter S. Speidl, Rosario V. Tripodi, Ulf Landmesser, Alberico L. Catapano, Angela Pirillo

Article2003

[Ongoing trials and future prospects].

Samuele Baldasseroni, Gianna Fabbri, Aldo Maggioni

Article2025

Statin intolerance in a real word setting of Italian cardiology centers: data from the BRING-UP Prevention study

Furio Colivicchi, Maurizio Giuseppe Abrignani, Marcello Arca, Maurizio Averna, Alberico L. Catapano, Stefania Angela Di Fusco, Andrea Di Lenarda, Gianna Fabbri, Francesco Fattirolli, Domenico Gabrielli, Michele Massimo Gulizia, Fabrizio Oliva, Carmine Riccio, Pier Luigi Temporelli, Aldo Maggioni

Preprint2018

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment

Eeva Sliz, Johannes Kettunen, Michael V. Holmes, Clare Oliver‐Williams, Charles Boachie, Qin Wang, Minna Männikkö, Sylvain Sebért, Robin Walters, Kuang Lin, Iona Y. Millwood, Robert B. Clarke, Liming Li, Naomi Rankin, Paul Welsh, Christian Delles, J. Wouter Jukema, Stella Trompet, Ian Ford, Markus Perola, Veikko Salomaa, Paul M Ridker, Zhengming Chen, Debbie A. Lawlor,